Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.

Ali, Amjad; Shah, Abdus Saboor; Ahmad, Ayaz

doi:10.1016/j.canlet.2014.07.045

Article (Scientific journals)

Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.

Ali, Amjad; Shah, Abdus Saboor; Ahmad, Ayaz

2014 • In Cancer Letters

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/182191

DOI
10.1016/j.canlet.2014.07.045

PubMed
25111898

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S0304383514004248-main.pdf

Author preprint (1.08 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

mutant p53; klf17; metastasis

Abstract :

[en] Kruppel-like-factor 17 (KLF17) is a negative regulator of metastasis and epithelial-mesenchymal-transition (EMT). However, its expression is downregulated in metastatic breast cancer that contains p53 mutations. Here, we show that mutant-p53 plays a key role to suppress KLF17 and thereby enhances cancer progression, which defines novel gain-of-function (GOF) of mutant-p53. Mutant-p53 interacts with KLF17 and antagonizes KLF17 mediated EMT genes transcription. Depletion of KLF17 promotes cell viability, decreases apoptosis and induces drug resistance in metastatic breast cancer cells. KLF17 suppresses cell migration and invasion by decreasing CD44, PAI-1 and Cyclin-D1 expressions. Taken together, our results show that KLF17 is important for the suppression of metastasis and could be a potential therapeutic target during chemotherapy.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Ali, Amjad ; Université de Liège > Département de pharmacie > Chimie médicale

Shah, Abdus Saboor

Ahmad, Ayaz

Language :

English

Title :

Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.

Publication date :

01 November 2014

Journal title :

Cancer Letters

ISSN :

0304-3835

eISSN :

1872-7980

Publisher :

Elsevier Science Ireland, Limerick, Ireland

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 June 2015

Statistics

Number of views

41 (2 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspect. Biol 2010, 2:a001008.
Bossi G., Lapi E., Strano S., Rinaldo C., Blandino G., Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25:304-309.
Lim L.Y., Vidnovic N., Ellisen L.W., Leong C.O. Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer 2009, 101:1606-1612.
Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25:304-317.
Lu X., Liu D.P., Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 2013, 32:2900-2906.
Heinlein C., Krepulat F., Lohler J., Speidel D., Deppert W., Tolstonog G.V. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int. J. Cancer 2008, 122:1701-1709.
King S.I., Purdie C.A., Bray S.E., Quinlan P.R., Jordan L.B., Thompson A.M., et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome. Breast Cancer Res 2012, 14:R40.
Liu D.P., Song H., Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010, 29:949-956.
Yan W., Chen X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J. Biol. Chem 2009, 284:12178-12187.
Di Agostino S., Strano S., Emiliozzi V., Zerbini V., Mottolese M., Sacchi A., et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10:191-202.
Freed-Pastor W.A., Mizuno H., Zhao X., Langerod A., Moon S.H., Rodriguez-Barrueco R., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
Yan W., Liu S., Xu E., Zhang J., Zhang Y., Chen X., et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene 2013, 32:599-609.
Fontemaggi G., Dell'Orso S., Muti P., Blandino G., Strano S. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 2010, 9:2464-2466.
Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res 2006, 12:1157-1167.
Gumireddy K., Li A., Gimotty P.A., Klein-Szanto A.J., Showe L.C., Katsaros D., et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol 2009, 11:1297-1304.
Sun Z., Han Q., Zhou N., Wang S., Lu S., Bai C., et al. MicroRNA-9 enhances migration and invasion through KLF17 in hepatocellular carcinoma. Mol. Oncol 2013, 7:884-894.
Ismail I.A., Kang H.S., Lee H.J., Kim J.K., Hong S.H. DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br. J. Cancer 2014, 110:1298-1306.
Ismail I.A., Kang H.S., Lee H.J., Chang H., Yun J., Lee C.W., et al. 2-Hydroxycinnamaldehyde inhibits the epithelial-mesenchymal transition in breast cancer cells. Breast Cancer Res. Treat 2013, 137:697-708.
Iwanicki M.P., Brugge J.S. Transcriptional regulation of metastatic [Id]entity by KLF17. Genome Biol 2009, 10:244.
Liu F.Y., Deng Y.L., Li Y., Zeng D., Zhou Z.Z., Tian D.A., et al. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma. Med. Oncol 2013, 30:425.
Cai X.D., Zhou Y.B., Huang L.X., Zeng Q.L., Zhang L.J., Wang Q.Q., et al. Reduced expression of Kruppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma. Biochem. Biophys. Res. Commun 2012, 418:67-73.
Ali A., Wang Z., Fu J., Ji L., Liu J., Li L., et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat. Commun 2013, 4:2667.
Fontemaggi G., Dell'Orso S., Trisciuoglio D., Shay T., Melucci E., Fazi F., et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol 2009, 16:1086-1093.
Knowell A.E., Patel D., Morton D.J., Sharma P., Glymph S., Chaudhary J. Id4 dependent acetylation restores mutant-p53 transcriptional activity. Mol. Cancer 2013, 12:161.
Dong P., Kaneuchi M., Xiong Y., Cao L., Cai M., Liu X., et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis 2014, 35:760-768.
van Vliet J., Crofts L.A., Quinlan K.G., Czolij R., Perkins A.C., Crossley M. Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics 2006, 87:474-482.
Montgomery N., Hill A., McFarlane S., Neisen J., O'Grady A., Conlon S., et al. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res 2012, 14:R84.
Yu Z., Wang L., Wang C., Ju X., Wang M., Chen K., et al. Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Nat. Commun 2013, 4:2812.
Sternlicht M.D., Dunning A.M., Moore D.H., Pharoah P.D., Ginzinger D.G., Chin K., et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol. Biomarkers Prev 2006, 15:2107-2114.
Liu W.B., Jiang X., Han F., Li Y.H., Chen H.Q., Liu Y., et al. LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer. Cell Death Dis 2013, 4:e882.